Preclinical Short-term and Long-term Safety of Human Bone Marrow Mesenchymal Stem Cells
Ziyang Liang,Guoyang Zhang,GuangTing Gan,Duolan Naren,Xiaoyan Liu,Hongyun Liu,Jiani Mo,Shengqin Lu,Danian Nie,Liping Ma
DOI: https://doi.org/10.1177/09636897231213271
2023-12-08
Cell Transplantation
Abstract:Cell Transplantation, Volume 32, Issue , January-December 2023. Mesenchymal stem cells (MSCs) have become a promising therapeutic method. More safety data are needed to support clinical studies in more diseases. The aim of this study was to investigate the short- and long-term safety of human bone marrow–derived MSCs (hBMMSCs) in mice. In the present study, we injected control (saline infusion only), low (1.0 × 106/kg), medium (1.0 × 107/kg), and high (1.0 × 108/kg) concentrations of hBMMSCs into BALB/c mice. The safety of the treatment was evaluated by observing changes in the general condition, hematology, biochemical indices, pathology of vital organs, lymphocyte subsets, and immune factor levels on days 14 and 150. In the short-term toxicity test, no significant abnormalities were observed in the hematological and biochemical parameters between the groups injected with hBMMSCs, and no significant damage was observed in the major organs, such as the liver and lung. In addition, no significant differences were observed in the toxicity-related parameters among the groups in the long-term toxicity test. Our study also demonstrates that mice infused with different doses of hBMMSCs do not show abnormal immune responses in either short-term or long-term experiments. We confirmed that hBMMSCs are safe through a 150-day study, demonstrating that this is a safe and promising therapy and offering preliminary safety evidence to promote future clinical applications of hBMMSCs in different diseases.
medicine, research & experimental,transplantation,cell & tissue engineering